Cholestatic Pruritus Associated with PBC: Understanding Unmet Patient Needs and Treatment Strategies

Annenberg Center for Health Sciences
  • 0.0 (0)
  • MEDICINE

Pruritus occurs in up to 70% of patients with primary biliary cholangitis (PBC), can be severe, and lead to increased morbidity-including worsening fatigue and quality of sleep. Standard of care treatment has relied on a variety of medications with limited effectiveness and tolerability adding to the patient disease burden. Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team.

Episodes

  1. 02/11/2025

    Interprofessional Patient Case

    Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

    5 min

  2. 02/11/2025

    Investigational Therapies

    Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

    5 min

  3. 02/11/2025

    Current Treatment Options

    Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

    16 min

  4. 02/11/2025

    Treatment Overview

    Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

    6 min

  5. 02/11/2025

    Diagnosis and Monitoring

    Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

    5 min

  6. 02/11/2025

    Introduction

    Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

    5 min
  • 6 Episodes

About

Pruritus occurs in up to 70% of patients with primary biliary cholangitis (PBC), can be severe, and lead to increased morbidity-including worsening fatigue and quality of sleep. Standard of care treatment has relied on a variety of medications with limited effectiveness and tolerability adding to the patient disease burden. Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team.

Information